# Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19

> **NCT04425252** · PHASE1,PHASE2 · COMPLETED · sponsor: **Clear Creek Bio, Inc.** · enrollment: 25 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Brequinar
- **OTHER:** Standard of Care

## Key facts

- **NCT ID:** NCT04425252
- **Lead sponsor:** Clear Creek Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-19
- **Primary completion:** 2020-12-29
- **Final completion:** 2021-01-12
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2022-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04425252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04425252, "Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04425252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*